A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy

• Status: Terminated
• Trial end date: 2018-02-01
• Target enrollment: 0
• Participant gender: All

Summary

To observe the decreased levels of low-density lipoprotein from baseline in patients with obesity-related glomerulopathy (ORG) after 12 weeks of Sevelamer Carbonate treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhi-Hong Liu, M.D.
• Treatments: Irbesartan; Sevelamer

Criteria

Inclusion Criteria:

• Clinical diagnosis of obesity

• diagnosed ORG by renal biopsy

• LDL>3.37mmol/L

• Proteinuria 0.5-3.5g/d

• eGFR (CKD-EPI formula) > 30ml/min

Exclusion Criteria:

• Other concomitant renal diseases

• Endocrine or drug-induced obesity;

• Type 2 diabetes

• eyes or obvious microscopic hematuria;

• Swallowing difficulty / severe gastrointestinal dysfunction

• intestinal obstruction;

• severe arrhythmia;

• Hypophosphatemia (<0.7mmol/L);

• allergic to Sevelamer Carbonate

• unable to well cooperate

• Females who are in the period of gestation or lactation, or refuse to use contraception;

• participated in other clinical trial of drug within three months